The cancer team working under Moderna’s Tal Zaks have been tinkering with various combinations of mRNA in mice to see how best they can use this technology to orchestrate an immune system attack. And today they’re highlighting a preclinical rodent study that indicates they could be on a promising path that’s taken them into human trials.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.Free Subscription